These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 8217364

  • 41. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
    Powis G, Gasdaska PY, Gallegos A, Sherrill K, Goodman D.
    Anticancer Res; 1995; 15(4):1141-5. PubMed ID: 7653992
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
    Siegel D, Gibson NW, Preusch PC, Ross D.
    Cancer Res; 1990 Nov 15; 50(22):7293-300. PubMed ID: 2121335
    [Abstract] [Full Text] [Related]

  • 44. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
    Workman P.
    Oncol Res; 1994 Nov 15; 6(10-11):461-75. PubMed ID: 7620214
    [Abstract] [Full Text] [Related]

  • 45. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    Lopez Lopez R, van Rijswijk RE, Wagstaff J, Pinedo HM, Peters GJ.
    Eur J Cancer; 1994 Nov 15; 30A(10):1545-9. PubMed ID: 7833116
    [Abstract] [Full Text] [Related]

  • 46. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
    Skibo EB, Xing C, Dorr RT.
    J Med Chem; 2001 Oct 25; 44(22):3545-62. PubMed ID: 11606119
    [Abstract] [Full Text] [Related]

  • 47. Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model.
    Guchelaar HJ, Vermes I, Koopmans RP, Reutelingsperger CP, Haanen C.
    Cancer Chemother Pharmacol; 1998 Oct 25; 42(1):77-83. PubMed ID: 9619762
    [Abstract] [Full Text] [Related]

  • 48. Assessment of micronucleus induction in murine SCCVII cells treated with various anticancer agents.
    Jeremic B, Shibamoto Y, Abe M.
    Chemotherapy; 1996 Oct 25; 42(4):266-72. PubMed ID: 8804794
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
    Woolley DE, Tetlow LC, Adlam DJ, Gearey D, Eden RD, Ward TH, Allen TD.
    Exp Cell Res; 2002 Feb 01; 273(1):65-72. PubMed ID: 11795947
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels.
    Migliaccio S, Wetsel WC, Fox WM, Washburn TF, Korach KS.
    Mol Endocrinol; 1993 Sep 01; 7(9):1133-43. PubMed ID: 8247015
    [Abstract] [Full Text] [Related]

  • 55. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar RE, Fiebig HH, Double JA.
    Eur J Cancer; 1993 Sep 01; 29A(6):897-906. PubMed ID: 8484984
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines.
    Bando T, Kasahara K, Shibata K, Numata Y, Nakatsumi Y, Fujimura M, Matsuda T.
    Anticancer Res; 1995 Sep 01; 15(3):769-72. PubMed ID: 7645956
    [Abstract] [Full Text] [Related]

  • 59. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
    Lambert PA, Kang Y, Greaves B, Perry RR.
    J Surg Res; 1998 Dec 01; 80(2):177-81. PubMed ID: 9878310
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.